$VPRO .0034 Huge DD Multi Dollar Value, New Management, New

New Post Public Reply Private Reply Replies (0) Message Board
MoneyMaker
$VPRO .0034 Huge DD Multi Dollar Value, New Management, New Website & Huge Products

Partners are Big

BRI Biopharmaceutical Research http://www.bripharm.com

CoreRX Pharma
http://www.corerxpharma.com

Spectrum Pharmaceutical Inc. $7.00+ on Nasdaq
http://www.sppirx.com

Oncobiologics
http://www.oncobiologics.com

Alpha Biologics
http://www.alphabiologics.com

Huge Documents Involving Gilead, Celgene, Amgen, Biogene Idec and So Many Top Pharmaceuticals...VIROPRO is a Steal considering the Competitor's Value.... 73 Page Pharmaceutical & Biotechnology 2014 Outlook >> https://www.google.ca/url?sa=t&source=web...7CmJfnK8QA

New Website >> http://www.viropro.net

Active SOS >> https://nvsos.gov/sosentitysearch/CorpDetails...amp;nt7=0j

Outstanding Shares 916,000,000

Float 39,000,000

Insiders Holdings 48,000,000

Institutional Holdings 631,000,000

INSTITUTIONAL HOLDERS

Spring Hill Bioventures Sdn Bhd
340,000,000

THG Capital Sdn Bhd
184,000,000

Intas Biopharmaceuticals Ltd.
106,916,666    

Employees

The Company has 34 employees.  Two of the employees are Viropro’s senior executive officers and seven are employees of BPD.  Under Alpha Biologics, there are 20 employees in Penang, Malaysia and 5 in Cambridge, UK.

Portfolio Valuation is Huge

Viropro estimates the combined, aggregate realizable value of its biosimilars portfolio to be in the range of $33 million to $42 million, depending upon market dynamics of the individual products.

Projected Revenues

The companies project that Viropro commercial and manufacturing royalties have the potential to grow to an annual revenue run rate of $60–$150 million for Viropro within 10 years . The partnership is planning to launch its first product by late 2014.

The products include biosimilar version of Avastin (bevacizumab), Erbitux (cetuximab), Herceptin (trastuzumab), Humira (adalimumab), Rituxan (rituximab) and a non-disclosed biological used for cancer and immune-disease indications.

New Management with Absolutely Huge Portfolios as of 2014

http://www.viropro.net/leadership-team/

The Board appointed Dr. Joseph J. Vallner as Acting President and Bruce A. Cohen as Chairman of the Board. Since 2009 Dr. Vallner has served as a consultant primarily to small pharmas/biotech companies and was previously President of ORUUS Pharma, a cancer drug delivery company, Lumera Corp., a company that developed products for electro-optics applications, which was a publicly traded company on NASDAQ during the time Dr. Vallner was its President and CEO, and President and CEO of Capnia, a company that developed nasal delivery of therapeutic gas for migraine and other inflammation disorders. Dr. Vallner received his BS degree in Pharmacy, his MS degree in hysical Chemistry and his PhD in Pharmaceutics (Biochemistry minor) from the University of Wisconsin. The Board is negotiating an employment agreement with Dr. Vallner.
 
Bruce A. Cohen has served as founding President and CEO of several biotech companies and assisted them with financings, including Vitapath Genetics, Inc. from 2008-2012, a personalized genetics company, Cellerant Therapeutics, Inc., from 2002-2007, a stem cell therapy company, and Acacia Biosciences, Inc. from 1997-2000, a bioinformatics-based functional genomics discovery company. Mr. Cohen was CFO of GeneSoft Pharmaceuticals from 2000-2001 and Vice President at SEQUUS Pharmaceuticals, Inc. from 1995-1997, a pharma company involved with liposome-based oncology and anti-infective drugs. Prior to these executive roles, Mr. Cohen was the President and COO of ViTel International and a management consultant with Monitor Company . Mr. Cohen has an MBA with distinction from Harvard Business School, and a BA and MA from Tufts University.


Viropro, Inc. and Oncobiologics, Inc. have signed a biosimilar collaboration agreement, under which Viropro will have the rights to manufacture six monoclonal antibody products being developed by Oncobiologics for commercialization in more than 70 emerging markets (excluding China).

Viropro will have commercialization rights to the six biosimilars for Malaysia. In addition, the companies will co-manage Viropro's Alpha Biologics biomanufacturing subsidiary in Penang, Malaysia.   

The biosimilars are generic versions of Humira, Rituxan, Avastin, Herceptin, Erbitux, and one other non-disclosed biotherapeutic. The companies project that Viropro commercial and manufacturing royalties have the potential to grow to an annual revenue rate of $60–$150 million in 10 years. The partnership plans to launch its first product by late 2014.

Competitors Capitalization

Lonza Group AG  (SWX:LONN)
$3.2 billion

Pharmaceutical Product Development, Inc. (Nasadaq PDI)
$3.8 billion

Cambrex Corporation (NYSE:CBM)
$210 million

Bioanalytical Systems, Inc. (Nasdaq:BASI)
$7.1 million

Viropro,Inc. (PINK :VPRO)
$2 million
Scroll down for more posts ▼

Top 10 Most Recent News Articles

NextPlat’s 150-Patient Test Has a Long Road Ahead

Updated Category News Views 82

A strip of pills can look mundane, yet it is where this entire NextPlat pitch either earns its keep or falls apart. PharmcoRx has signed a partner pharmacy agreement with MedSure Systems for a 150-patient Medicare medication-adherence pilot in South Florida. That is a small starting line, no two ways around it. Still, the mechanics are more interesting than another vague...

Continue Reading
Youdao Sets December AGM With No Vote on the Table

Updated Category News Views 219

A shareholder meeting without a vote is more temperature check than showdown, and that is exactly what Youdao has scheduled for December 17, 2026. The company will gather shareholders from 3:00 p.m. to 5:00 p.m. Beijing time at its Beijing office, but it has made one point painfully clear: no proposal will be submitted for shareholder approval. For holders of NYSE: DAO,...

Continue Reading
Nvidia Faces SEC Probe Report and New Lawsuit Stakes

Updated Category News Views 137

Silicon Valley's favorite growth machine has stumbled into the sort of fog investors hate most: regulatory questions, leadership upheaval, and a stock-price reaction with no clean answer attached. Reports cited in the lawsuit update say the Securities and Exchange Commission has opened a civil probe into NVIDIA's investor disclosures following former CEO Jensen Huang's...

Continue Reading
Fervo’s 46% Slide Puts Geothermal Claims Under Fire

Updated Category News Views 105

A 46% haircut from an IPO price has a way of stripping the paint off a growth story. Fervo Energy closed at $14.33 after the October 6 report cited in Hagens Berman’s announcement, well below its $27 IPO price from last May. That does not prove the report is right. It does mean NASDAQ:FRVO investors are staring at questions that go straight to the economic spine of...

Continue Reading
TD Pledges $2 Billion to Financial Strength by 2036

Updated Category News Views 66

A Longer-Term Bet on Household Resilience A bank’s community budget rarely grabs the market by the collar, but TD’s new target deserves more than a polite nod. The bank says it will direct $2 billion, or US$1.4 billion, toward helping people build financial strength across North America over the next decade. That is a sizable commitment, even for an institution with...

Continue Reading
Lowe's Dec. 9 Conference Puts Strategy on the Clock

Updated Category News Views 67

A Calendar Entry With Real Weight December 9 is not earnings day, but it is the sort of date shareholders ought to circle anyway. Lowe's plans to hold its 2026 Analyst and Investor Conference at 8 a.m. Eastern time in New York City, with a live webcast available for those not sitting in the room. For owners of NYSE:LOW, these gatherings can be more useful than the usual...

Continue Reading
Cineverse Sets Wolf Creek Return for March 19, 2027

Updated Category News Views 64

A sunburned serial killer is heading back to theaters, and Cineverse has finally put a date on it: March 19, 2027. WOLF CRE3K, formerly called Wolf Creek: Legacy, brings John Jarratt back as Mick Taylor for the third film in the Australian horror franchise. For NASDAQ:CNVS investors, this is not the kind of announcement that lets anyone pencil in revenue with a straight...

Continue Reading
MSD's AI Drug Bet Has Promise, but Plenty to Prove

Updated Category News Views 104

A promising molecule remains a very expensive guess until biology agrees. That is the sober lens for MSD's newly announced research collaboration with Isomorphic Labs: potentially meaningful science, certainly interesting strategic positioning, and absolutely no reason yet to start penciling in product sales. One Oncology Target, Not a Finished Drug On November 19, 2026,...

Continue Reading
Royce Global Trust's Discount Is Still the Whole Debate

Updated Category News Views 67

A $3.03 gap is staring investors right in the face. As of October 31, 2026, Royce Global Trust carried a net asset value of $17.51 per share while the market price sat at $14.48. That works out to roughly a 17.3% discount to NAV, and with a closed-end fund, that discount is not some footnote shoved under the table. It is a major part of the return story, good or bad. The...

Continue Reading
Fayetteville Auction Puts Two Retail Sites Into Play

Updated Category News Views 119

Two lots staring across Sycamore Dairy Road are about to get a public price tag, and that is usually where the real estate story stops being polite. Iron Horse Auction Co. plans to sell a commercial showroom at 3618 Sycamore Dairy Road and a former batting cage facility at 3701 Sycamore Dairy Road through an online-only auction closing Dec. 9 beginning at 2 p.m. They sit...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding the Impact of Tariff Uncertainty on Canada

Updated Category News Views 274

Revisiting Canada's Economic Outlook Amid Tariff Uncertainty The Canadian economy has faced various challenges recently, but the specter of global tariff uncertainty looms larger this year. According to recent insights, there is a subdued growth expectation as businesses and consumers alike brace for the ripple effects of trade tensions. Projections indicate that Canada's...

Continue Reading
Rising Innovations Set to Propel Multilayer Varistor Market Growth

Updated Category News Views 106

Understanding the Growth of the Multilayer Varistor Market The multilayer varistor market is on the brink of an impressive expansion. With a projected market value rising from approximately US$ 0.5 billion to US$ 1.1 billion by the end of the forecast period, it reflects an estimated compound annual growth rate (CAGR) of 6.9%. This growth is largely spurred by increasing...

Continue Reading
Public Opinion Insights Revealed in Kansas Speaks Survey

Updated Category News Views 269

2025 Kansas Speaks Survey Highlights Public Sentiment The Docking Institute of Public Affairs has conducted the annual Kansas Speaks Survey, which captures the voices of the Kansas populace on critical issues. This year, a diverse panel of 526 adult residents was engaged in online discussions to share their thoughts on a variety of topics affecting their daily lives....

Continue Reading
JP Morgan's $50 Million Debut on Solana's Blockchain Era

Updated Category News Views 129

JP Morgan Embraces Blockchain Technology JP Morgan Chase & Co (NYSE: JPM) has recently embarked on a transformative journey by issuing $50 million in U.S. commercial paper directly on the innovative Solana (CRYPTO: SOL) blockchain. This significant move is not just a financial transaction; it symbolizes a pivotal moment in the adoption of blockchain technology by major...

Continue Reading
Reddit Inc Sees Notable Stock Surge Following Trading Alerts

Updated Category News Views 341

Reddit Inc Experiences Remarkable Stock Movements Reddit Inc (NYSE: RDDT) recently captured attention in the financial markets as it experienced a significant Power Inflow alert. This alert is not just a passing moment but a critical bullish signal that traders closely monitor, as it provides insights into order flow analytics from both institutional and retail investors....

Continue Reading